Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

HIV-HCV Coinfection.

Sethi A, Sterling RK.

Gastroenterol Hepatol (N Y). 2006 May;2(5):357-365.

2.

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S.

J Clin Exp Hepatol. 2015 Sep;5(3):221-38. doi: 10.1016/j.jceh.2015.09.002. Epub 2015 Sep 21. Review.

3.

Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.

Zhang S, Rust G, Cardarelli K, Felizzola J, Fransua M, Stringer HG Jr.

AIDS Care. 2015;27(7):829-35. doi: 10.1080/09540121.2015.1021745. Epub 2015 Mar 27.

4.

Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

Puri P, Anand AC, Saraswat VA, Acharya SK, Sarin SK, Dhiman RK, Aggarwal R, Singh SP, Amarapurkar D, Arora A, Chhabra M, Chetri K, Choudhuri G, Dixit VK, Duseja A, Jain AK, Kapoor D, Kar P, Koshy A, Kumar A, Madan K, Misra SP, Prasad MV, Nagral A, Puri AS, Jeyamani R, Saigal S, Shah S, Sharma PK, Sood A, Thareja S, Wadhawan M.

J Clin Exp Hepatol. 2014 Jun;4(2):117-40. doi: 10.1016/j.jceh.2014.06.001. Epub 2014 Jun 24. Review.

5.

Impact of methamphetamine on infection and immunity.

Salamanca SA, Sorrentino EE, Nosanchuk JD, Martinez LR.

Front Neurosci. 2015 Jan 12;8:445. doi: 10.3389/fnins.2014.00445. eCollection 2014. Review.

6.

Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda.

Kyeyune R, Saathoff E, Ezeamama AE, Löscher T, Fawzi W, Guwatudde D.

BMC Infect Dis. 2014 Sep 10;14:496. doi: 10.1186/1471-2334-14-496.

7.

Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients.

Frulio N, Trillaud H, Perez P, Asselineau J, Vandenhende M, Hessamfar M, Bonnet F, Maire F, Delaune J, De Ledinghen V, Morlat P.

BMC Infect Dis. 2014 Jul 21;14:405. doi: 10.1186/1471-2334-14-405.

8.

Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection.

Erqou S, Mohanty A, Murtaza Kasi P, Butt AA.

ISRN Gastroenterol. 2014 Apr 7;2014:764540. doi: 10.1155/2014/764540. eCollection 2014.

9.

German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients.

Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, van Lunzen J, Schulze Zur Wiesch J.

AIDS Res Ther. 2014 Jul 1;11:16. doi: 10.1186/1742-6405-11-16. eCollection 2014.

10.

Disparities and risks of sexually transmissible infections among men who have sex with men in China: a meta-analysis and data synthesis.

Chow EP, Tucker JD, Wong FY, Nehl EJ, Wang Y, Zhuang X, Zhang L.

PLoS One. 2014 Feb 24;9(2):e89959. doi: 10.1371/journal.pone.0089959. eCollection 2014.

11.

Hepatitis C Virus and HIV Type 1 Co-Infection.

Gupta P.

Infect Dis Rep. 2013 Jun 6;5(Suppl 1):e7. doi: 10.4081/idr.2013.s1.e7. eCollection 2013 Jun 6. Review.

12.

Rapid diagnostic HCV antibody assays.

Smith BD, Jewett A, Drobeniuc J, Kamili S.

Antivir Ther. 2012;17(7 Pt B):1409-13. doi: 10.3851/IMP2470. Epub 2012 Dec 7. Review.

13.

Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?

Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL.

J Addict Med. 2012 Sep;6(3):179-85. doi: 10.1097/ADM.0b013e318257377f.

14.

The influence of treatment with pegylated interferon-alfa and ribavirin on neutrophil function and death in patients with HIV/HCV coinfection.

Jablonowska E, Wojcik K, Nocun M.

Viral Immunol. 2012 Apr;25(2):166-72. doi: 10.1089/vim.2011.0078. Epub 2012 Feb 10.

15.

An interrupted time series evaluation of a hepatitis C intervention for persons with HIV.

Proeschold-Bell RJ, Hoeppner B, Taylor B, Cohen S, Blouin R, Stringfield B, Muir AJ.

AIDS Behav. 2011 Nov;15(8):1721-31. doi: 10.1007/s10461-010-9870-1.

16.

Hepatitis C infection in HIV-1 natural viral suppressors.

Sajadi MM, Shakeri N, Talwani R, Redfield RR.

AIDS. 2010 Jul 17;24(11):1689-95. doi: 10.1097/QAD.0b013e32833a2a32.

17.

Nutrition issues in chronic drug users living with HIV infection.

Hendricks K, Gorbach S.

Addict Sci Clin Pract. 2009 Apr;5(1):16-23.

18.

Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach.

Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, Mican JM, Suffredini A, Masur H, Polis MA, Kottilil S.

AIDS. 2008 Jul 31;22(12):1433-9. doi: 10.1097/QAD.0b013e328304dfe7.

19.

Methamphetamine enhances Hepatitis C virus replication in human hepatocytes.

Ye L, Peng JS, Wang X, Wang YJ, Luo GX, Ho WZ.

J Viral Hepat. 2008 Apr;15(4):261-70. doi: 10.1111/j.1365-2893.2007.00940.x.

20.

Therapeutic issues in HIV/HCV-coinfected patients.

Sulkowski MS, Benhamou Y.

J Viral Hepat. 2007 Jun;14(6):371-86. Review.

Supplemental Content

Support Center